Gutenberg Open Science: Emerging immunotherapy for HCC : a guide for hepatologists

Please use this identifier to cite or link to this item: http://doi.org/10.25358/openscience-8613

Full metadata record

DC Field	Value	Language
dc.contributor.author	Foerster, Friedrich	-
dc.contributor.author	Gairing, Simon Johannes	-
dc.contributor.author	Ilyas, Sumera Irie	-
dc.contributor.author	Galle, Peter R.	-
dc.date.accessioned	2023-01-19T10:59:41Z	-
dc.date.available	2023-01-19T10:59:41Z	-
dc.date.issued	2022	-
dc.identifier.uri	https://openscience.ub.uni-mainz.de/handle/20.500.12030/8629	-
dc.description.abstract	HCC is one of the most common cancers worldwide, and the third leading cause of cancer-related death globally. HCC comprises nearly 90% of all cases of primary liver cancer. Approximately half of all patients with HCC receive systemic therapy during their disease course, particularly in the advanced stages of disease. Immuno-oncology has been paradigm shifting for the treatment of human cancers, with strong and durable antitumor activity in a subset of patients across a variety of malignancies including HCC. Immune checkpoint inhibition with atezolizumab and bevacizumab, an antivascular endothelial growth factor neutralizing antibody, has become first-line therapy for patients with advanced HCC. Beyond immune checkpoint inhibition, immunotherapeutic strategies such as oncolytic viroimmunotherapy and adoptive T-cell transfer are currently under investigation. The tumor immune microenvironment of HCC has significant immunosuppressive elements that may affect response to immunotherapy. Major unmet challenges include defining the role of immunotherapy in earlier stages of HCC, evaluating combinatorial strategies that use targeting of the immune microenvironment plus immune checkpoint inhibition, and identifying treatment strategies for patients who do not respond to the currently available immunotherapies. Herein, we review the rationale, mechanistic basis and supporting preclinical evidence, and available clinical evidence for immunotherapies in HCC as well as ongoing clinical trials of immunotherapy.	en_GB
dc.description.sponsorship	Gefördert durch die Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 491381577	de
dc.language.iso	eng	de
dc.rights	CC BY-NC	*
dc.rights.uri	https://creativecommons.org/licenses/by-nc/4.0/	*
dc.subject.ddc	610 Medizin	de_DE
dc.subject.ddc	610 Medical sciences	en_GB
dc.title	Emerging immunotherapy for HCC : a guide for hepatologists	en_GB
dc.type	Zeitschriftenaufsatz	de
dc.identifier.doi	http://doi.org/10.25358/openscience-8613	-
jgu.type.dinitype	article	en_GB
jgu.type.version	Published version	de
jgu.type.resource	Text	de
jgu.organisation.department	FB 04 Medizin	de
jgu.organisation.number	2700	-
jgu.organisation.name	Johannes Gutenberg-Universität Mainz	-
jgu.rights.accessrights	openAccess	-
jgu.journal.title	Hepatology	de
jgu.journal.volume	75	de
jgu.journal.issue	6	de
jgu.pages.start	1604	de
jgu.pages.end	1626	de
jgu.publisher.year	2022	-
jgu.publisher.name	Wiley Interscience	de
jgu.publisher.place	New York, NY u.a.	de
jgu.publisher.issn	1527-3350	de
jgu.organisation.place	Mainz	-
jgu.subject.ddccode	610	de
jgu.publisher.doi	10.1002/hep.32447	de
jgu.organisation.ror	https://ror.org/023b0x485	-
jgu.subject.dfg	Lebenswissenschaften	de
Appears in collections:	DFG-491381577-H

Files in This Item:

	File	Description	Size	Format
	emerging_immunotherapy_for_hc-20230119115733564.pdf		1.51 MB	Adobe PDF	View/Open

Show simple item record